Abstract: JAK inhibitors have been reported to be effective in the treatment of vasculitis. The data of 3 patients with cutaneous vasculitis treated with JAK inhibitors were retrospectively analyzed. Patient 1, a 32-year-old female, was diagnosed with reticular livid vasculitis. After treatment with abrocitinib 100 mg/d, the ecchymosis and ulcer were significantly relieved within 1 week, and the skin lesions were controlled without recurrence 4 weeks later. Patient 2, a 48-year-old male, was diagnosed with leukocytoclastic vasculitis. He was treated with 15 mg/d of upadacitinib sustained-release tablets. The lesions improved significantly after 12 weeks and no recurrence was observed after drug withdrawal. Patient 3, a 39-year-old female, was diagnosed with cutaneous allergic vasculitis. After the treatment with abrocitinib 100 mg/d, necrotic scabs fell off, and ecchymosis subsided without recurrence up to now. JAK inhibitors have good efficacy and safety in the treatment of cutaneous vasculitis, but its long-term efficacy and safety still need further clinical observation.

Key words: livedoid vasculitis, hypersensitity vasculitis, abrocitinib, upadacitinib